Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo by Rongvaux, Anthony et al.
Human thrombopoietin knockin mice efﬁciently
support human hematopoiesis in vivo
Anthony Rongvauxa,b, Tim Willingera,b, Hitoshi Takizawab,c,d, Chozhavendan Rathinama,b, Wojtek Auerbache,
Andrew J. Murphye, David M. Valenzuelae, George D. Yancopoulose, Elizabeth E. Eynona,b,f, Sean Stevensb,e,1,
Markus G. Manzb,c,d,2,3, and Richard A. Flavella,b,f,2,3
aDepartment of Immunobiology and fHoward Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520; bBill and Melinda Gates
Foundation Grand Challenges in Global Health GC#4 Consortia, Yale University School of Medicine, New Haven, CT 06520; cDivision of Hematology, University
Hospital Zurich, 8091 Zurich, Switzerland; dInstitute for Research in Biomedicine, 6500 Bellinzona, Switzerland; and eRegeneron Pharmaceuticals, Inc.,
Tarrytown, NY 10591
Contributed by Richard A. Flavell, December 29, 2010 (sent for review November 3, 2010)
Hematopoietic stem cells (HSCs) both self-renew and give rise to
all blood cells for the lifetime of an individual. Xenogeneic mouse
models are broadly used to study human hematopoietic stem and
progenitor cell biology in vivo. However, maintenance, differenti-
ation, and function of human hematopoietic cells are suboptimal
in these hosts. Thrombopoietin (TPO) has been demonstrated as
a crucial cytokine supporting maintenance and self-renewal of
HSCs. We generated RAG2−/−γc−/− mice in which we replaced
the gene encoding mouse TPO by its human homolog. Homozy-
gous humanization of TPO led to increased levels of human en-
graftment in the bone marrow of the hosts, and multilineage
differentiation of hematopoietic cells was improved, with an in-
creased ratio of myelomonocytic verus lymphoid lineages. More-
over, maintenance of human stem and progenitor cells was
improved, as demonstrated by serial transplantation. Therefore,
RAG2−/−γc−/− TPO-humanized mice represent a useful model to
study human hematopoiesis in vivo.
Hematopoietic stem cells (HSCs) are rare cells, deﬁned bytwo major properties: lifelong self-renewal, and differenti-
ation capacity to all mature hematopoietic lineage cells (1, 2). To
ensure HSC pool homeostasis, it is believed that upon cell di-
vision, HSCs generate on average one functional HSC, whereas
the other offspring cell might undergo a highly organized pro-
gram of differentiation and cellular expansion, during which
multiple lineages of committed progenitors and, ultimately, ter-
minally differentiated cells are produced.
Mouse hematopoiesis has been extensively studied during the
past decades, leading to the identiﬁcation and functional char-
acterization of immunophenotypically deﬁned cellular popula-
tions, highly enriched in stem and progenitor cells in vivo (2).
However, prospective experimental in vivo studies of human
lifelong hematopoiesis have been limited by obvious practical
and ethical restrictions.
To circumvent this limitation, several substitute, xenogeneic
transplantation models for in vivo human hematopoiesis studies
have been developed (3). Of these models, transplantation of
human hematopoietic cells into immunodeﬁcient mice has been
broadly established in experimental hematopoiesis laboratories
(3–8). Themodels most commonly used today rely on the BALB/c
Rag2−/−γc−/− or NOD-SCID γc−/− strains of mice (9–11). Both
strains are highly immunodeﬁcient, lacking B, T, andNK cells, and
their genetic background is permissive for human hematopoietic
engraftment and differentiation. Upon human CD34+ hemato-
poietic stem and progenitor cell transplantation, most human
hematopoietic populations (including B cells, T cells, monocytes,
dendritic cells, erythrocytes, and platelets) can develop and are
detectable in these models (7, 8, 10–12). However, in those chi-
meric animals, there is a bias toward lymphoid development with
initially high B-cell counts, myelomonocytic development is rela-
tivelyminor, and engraftment levels usually start to decline 4–6mo
after transplantation. Moreover, the xenogenic engraftment of
human cells intomice requires transplantation of large numbers of
cells comparedwith the numbers that are sufﬁcient for the optimal
engraftment of mouse hematopoietic stem and progenitor cells
into mice, or human cells into humans, respectively (13). Fur-
thermore, in contrast to mouse HSCs transplanted into mouse
recipients (14), human HSCs do not expand, and there is no de-
ﬁnitive evidence for lifelongmaintenance in the xenogeneicmouse
environment (13). Thus, the mouse background provides a sub-
optimal environment to study the physiology of human HSCs. We
therefore hypothesized that this defect might be due to absence or
limited cross-reactivity of growth factors required to support the
function and maintenance of HSCs (13, 15).
Thrombopoietin (TPO) was initially identiﬁed as a growth
factor that promotes the development of megakaryocytes and
platelets (16–22). TPO is constitutively produced by the liver and
the kidneys and released into the blood circulation. The receptor
for TPO, c-Mpl, is expressed by hematopoietic stem and pro-
genitor cells in the bone marrow. C-Mpl is also expressed on
circulating platelets. However, the binding of TPO on platelets
does not activate any signaling pathway. Thus, thrombocytes act
as a sink or scavengers for TPO and contribute to negative reg-
ulation of thrombopoiesis. Subsequently, TPO has been recog-
nized for its important function to support the expansion and self-
renewal of HSCs (23, 24). In adult mice, TPO deﬁciency leads to
reduced numbers of HSCs, and the presence of TPO is needed to
maintain adult HSCs in quiescence (25, 26). Furthermore, TPO
is required to support posttransplantation expansion of mouse
HSCs, necessary to replenish the hematopoietic compartment of
irradiated hosts (23, 26). Interestingly, it has been demonstrated
that osteoblastic cells involved in forming the HSC “niche” in
the bone marrow produce TPO, critical for HSC function and
maintenance (25).
Although mouse and human TPO are both-sided cross-reactive
to the respective cognate receptorswhenusedat supraphysiological
doses in vitro, afﬁnity and biologic activity might differ when the
cytokine acts at limiting, physiological doses in context of an in
vivo environment, particularly in themicroenvironment of theHSC
niche in the bone marrow. We thus hypothesized that mouse TPO
might not provide an appropriate stimulus to the human c-Mpl
receptor in vivo and, therefore, could account for the impaired
properties of human HSCs in the mouse environment. To correct
this potential defect, we replaced the gene encodingmouseTPOby
its human counterpart in Rag2−/−γc−/−mice.
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Thrombopoietin Gene Replacement and Expression Analysis. To re-
place the gene encoding mouse TPO by its human homolog, we
generated a targeting vector by using the VELOCIGENE tech-
nology (27). This vector was designed to replace the sequence
encompassing the ORF of Tpo, but to maintain the promoter
and 5′ UTR of mouse origin (Fig. S1). This targeting construct
was electroporated into F1 BALB/c × 129 Rag2+/−γcY/− ES cells,
and correctly targeted ES cell clones were identiﬁed by real-time
PCR (27). Chimeras were generated and their progeny were
intercrossed to obtain Rag2−/−γc−/− mice with wild-type Tpo
(TPOm/m), heterozygous (TPOh/m), or homozygous (TPOh/h)
TPO gene replacement.
To determine whether human TPO is faithfully expressed in
these mice, we ﬁrst extracted total RNA from a variety of organs
from a TPOh/m mouse, and we observed a similar pattern of ex-
pression for bothmouse and humanmRNAencoding TPObyRT-
PCR (Fig. 1A). Next, we compared the expression in three tissues
or cell types known to express TPO (liver, kidney, and mesen-
chymal multipotent stromal cells) from TPOm/m, TPOh/m, and
TPOh/h mice. We detected the expression of mouse Tpo in sam-
ples from TPOm/m and TPOh/m mice, whereas human TPO was
expressed in TPOh/m and TPOh/h (Fig. 1B). We also measured the
concentrations of TPO protein in the serum of the targeted mice.
Mouse TPO was detected in TPOm/m and TPOh/m animals and
human TPO in TPOh/m and TPOh/h (Fig. 1C). The concentrations
measured for human TPO were ≈10-fold lower than mouse TPO.
However, this difference is consistent with the respective physio-
logical concentrations reported in healthy human andmouse (Fig.
1C). The expression of human TPO is highly regulated at the
posttranscriptional level by mechanisms that involve alternative
splicing and restriction of the initiation of translation (28, 29).
These mechanisms ensure that the serum concentration of TPO is
maintained at a low level. Patients carrying mutations leading to
dysregulated translation of TPO have increased levels of circu-
lating TPO and develop hereditary thrombocythaemia (29). The
posttranscriptional mechanisms of mouse TPO have not been
studied in detail. Nevertheless, these observations suggest that the
concentrations of human TPO measured in the serum of TPOh/h
mice reﬂect physiological human values, which are of importance
for normal human hematopoieisis.
Improved Human Engraftment Levels in Bone Marrow of TPOh/h
Recipient Mice. We then engrafted 2 × 1.5 Gy irradiated new-
born Rag2−/−γc−/−TPOm/m, TPOh/m, and TPOh/h mice with hu-
man CD34+ cells puriﬁed from cord blood or fetal liver and
analyzed engraftment in bone marrow 3–4 mo or 6–7 mo later.
Although the total cellularity was comparable in both groups
(Fig. S2 A and B), we observed a signiﬁcant increase in the
percentages (Fig. 2 A and B and Fig. S2B) and absolute numbers
(Fig. 2C and Fig. S2 B and C) of human hematopoietic cells
(hCD45+) in bone marrow of TPOh/h compared with TPOm/m
recipients at both time points. In contrast, we did not observe any
improvement in human engraftment in the bone marrow of
heterozygous TPOh/m recipients (Fig. S2E), suggesting that
complete mouse Tpo deﬁciency and/or two copies of the human
TPO allele are required to support human hematopoiesis.
Interestingly, TPOh/h recipients also displayed a lower en-
graftment variability, with an at least 80% human chimerism in
75% of the mice at 3–4 mo (Fig. 2B). The effect of homozygous
TPO replacement did not depend on the source of the human
CD34+ cells, because a similar increase in chimerism in TPOh/h
hosts was observed with cells derived from cord blood and from
fetal liver (Fig. S2D). Finally, although numbers of human cells
declined in TPOm/m hosts between the early and later time
Fig. 1. Faithful tissue-speciﬁc expression of human TPO in knock-in mice. (A)
RT-PCR analysis of mouse TPO (mTpo) and human TPO (hTPO) expression in
different tissues of a Rag2+/−γcY/− TPOh/m mouse. Mouse Rpl13a was used as
housekeeping gene. (B) RT-PCR analysis of mTpo and hTPO expression in liver,
kidney, and mesenchymal multipotent stromal cells (MSCs) of Rag2−/−γc−/−
TPOm/m, TPOh/m, and TPOh/h mice. (C) Concentrations of mouse and human
TPO proteins measured by ELISA in serum of TPOm/m, TPOh/m, and TPOh/h mice
(in pg/mL, mean ± SD, n = 7–9). ND, not detected. The normal ranges in-
dicated are from R&D Systems, Thrombopoietin Quantikine kits.
Fig. 2. Improved human engraftment levels in bone marrow of TPOh/h re-
cipient mice. (A) Representative FACS analysis of human and mouse CD45+
cells in bone marrow of TPOm/m and TPOh/h mice 3–4 mo after engraftment.
Percentages of mouse and human CD45+ cells among the total CD45+ cell
populations are indicated. (B) Percentages of human CD45+ cells in the bone
marrow 3–4 mo (Left; n = 42–53) or 6–7 mo (Right; n = 20–25) after trans-
plantation. Each symbol represents an individual mouse; horizontal bars
indicate mean values. (C) Absolute numbers of human CD45+ cells in the
bone marrow of the same animals as in B.
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points, they remained constant in TPOh/h animals (Fig. 2C and
Fig. S2C). These results are consistent with the previously de-
scribed functions of TPO in the mouse. First, TPO favors the
expansion of HSCs after transplantation into irradiated recipient
mice, leading to increased engraftment levels (23, 26); second, it
favors the maintenance of adult HSCs, leading to sustained he-
matopoiesis throughout adult life (26).
Effect of TPO Humanization on Mouse and Human Platelets. Because
TPO is well-known for its nonredundant function on thrombo-
poiesis (22), we determined whether TPO humanization affected
platelet development. Humanization of both alleles of the TPO
gene led to an approximately twofold reduction in mouse blood
platelet counts of nonengrafted Rag2−/−γc−/− mice (Fig. 3A).
After engraftment with human cells, we found that the counts of
mouse platelets in TPOh/h mice were further decreased, to <25%
of normal values (Fig. 3D). The ratio of human to mouse
platelets (Fig. 3 B and C), as well as the absolute counts of human
platelets (Fig. 3E), tended to be higher in TPOh/h mice than
in TPOm/m, but none of these differences reached statistical sig-
niﬁcance. Furthermore, the percentage of bone marrow mega-
karyocytes (CD41a+ cells) among human cells was comparable in
both strains (Fig. 3F). The mouse population of megakaryocytes
(CD42b+) was also unaffected by the gene replacement in both
nonengrafted and engrafted mice. These results demonstrate that
levels or biologic activity of human TPO reached by our knock-in
strategy are not sufﬁcient to fully replacemouse TPO function and
furthermore suggest that human TPO on its own is not sufﬁcient
to support human thrombopoiesis in the mouse environment.
Multilineage Hematopoiesis in TPO-Humanized Mice. Next, we de-
termined whether human TPO could favor multilineage differ-
entiation of human hematopoietic stem and progenitor cells in
vivo. As previously reported (10, 11), the engrafted human cells
predominantly gave rise to B cells (CD19+) in wild-type Rag2−/−
γc−/− hosts (61.51 ± 4.71% of the human cells in the spleen,
mean ± SEM, n = 32) with, compared with hematopoiesis in
humans, only a small fraction of myeloid cells. When we com-
pared TPOm/m and TPOh/h recipients, we observed a signiﬁcant
increase in the frequency and absolute numbers of CD33+ mye-
loid cells in the bone marrow of TPOh/h mice (Fig. 4 A and B and
Fig. S3A). This increase was mostly due to granulocytes (CD33+
CD66hiSSChi cells), whereas the fraction of monocytes (CD33hiC-
D66loCD14+) was almost similar in both strains (Fig. 4 A,C, andD
and Fig. S3 B and C). The percentage of myeloid cells (both gran-
ulocytes and monocytes) was also signiﬁcantly increased in the
peripheral blood of TPOh/h animals (Fig. S3D–F). Accordingly, we
found that the population of bone marrow progenitors phenotypi-
cally described as highly enriched in granulocyte-monocyte pro-
genitors (30) (GMP; Lin−CD34+CD38+CD123loCD45RA+) was
increased relative to thepopulationof commonmyeloidprogenitors
(CMP; Lin−CD34+CD38+CD123loCD45RA−) (Fig. 4E).
Effect of TPO Humanization on Mouse and Human Hematopoietic
Stem and Progenitor Cells. We next analyzed the effect of human
TPO on the number and function of cellular populations
enriched for HSCs and progenitor cells. Genetic deletion of TPO
leads to a reduction of HSCs in adult mice (26). To determine
whether TPO humanization affects the mouse population immu-
nophenotypically deﬁned as containing mouse HSCs, we com-
pared the percentages of mouse lineage-negative Sca1+ c-Kit+
cells in bone marrow of nonengrafted TPOm/m, TPOh/m, and
TPOh/h adult mice. We observed a signiﬁcant reduction in the
percentage of these cells in both TPOh/m and TPOh/h mice com-
paredwithTPOm/m (Fig. 5A andB), suggesting that humanTPO is
either not fully cross-reactive on the mouse receptor or is not
available in sufﬁcient amounts to support the mouse cells in this
knock-in setting.
We then characterized the human CD34+ populations in the
bonemarrowof engraftedTPOm/m andTPOh/h hosts.HumanHSCs
with long-term repopulating potential are contained in the
Lin−CD34+CD38− cell fraction (5, 31–33). The percentage of
CD34+ cells among the human CD45+ population was slightly
increased inTPOh/hmice (12.39± 0.79%vs. 10.00± 0.81%,mean±
SEM, n= 43–53, P= 0.037). We also observed a small (1.5-fold)
but statistically signiﬁcant increase in the percentage of CD38−
cells within the CD34+ population in TPOh/h compared with
TPOm/m recipients (Fig. 5 C and D). Overall, it resulted in a
signiﬁcant increase (≈2.8-fold) of absolute numbers of CD34+
CD38− cells in TPO-humanized mice (Fig. 5E). Next, we char-
acterized the Lin−CD34+CD38− population based on the ex-
pression of CD90 and CD45RA. The CD90+CD45RA− fraction
Fig. 3. Effect of TPO humanization on mouse and human platelets. (A) Platelet counts in the blood of adult nonengrafted mice. P < 0.0001 (one-way
ANOVA, n = 7–17; P values calculated with the Tukey post hoc test). (B) Representative FACS analysis of mouse (mCD61+) and human (hCD41a+) platelets in the
blood of TPOm/m and TPOh/h mice 3–4 mo after engraftment. The numbers indicate percentages among total events. (C) Human platelet chimerism, de-
termined by FACS, in TPOm/m and TPOh/h mice (n = 19–22). Only mice with a percentage of human CD45+ cells in the blood >5% were included in this analysis.
(D and E) Counts of mouse (mCD61+; D) and human (hCD41a+; E) platelets in the blood. (F) Human megakoryocyte percentages (CD41a+) among human
CD45+ cells in the bone marrow.









has been described as highly enriched in long-term stem cells that
are functionally able to establish multipotent hematopoiesis in
vivo and to generate successful secondary transplants (34). We
measured a signiﬁcantly higher proportion of this CD90+
CD45RA− cell population in the Lin−CD34+CD38− fraction
from TPOh/h compared with TPOm/m (Fig. 5 F and G). Thus,
based on cell surface immunophenotype, human TPO favors
populations of cells known to be highly enriched for HSCs.
To address the functional properties of this cell population, we
puriﬁed human CD34+ cells from the bone marrow of TPOm/m
and TPOh/h mice and assessed them in methylcellulose colony
formation assays in vitro. The formation of CFU-GEMM, CFU-
G, and CFU-M was modestly higher in human CD34+ cell sam-
ples isolated from TPOh/h compared with TPOm/m mice (Fig. S4).
The capacity of HSC to maintain and/or self-renew in vivo is
best demonstrated functionally by successful secondary trans-
plants. “Scid repopulating cells” (SRCs) that serially engraft in
mice represent the surrogate experimental “gold standard” for
human HSC function (35). We therefore puriﬁed human CD34+
cells from bonemarrow of TPOm/m and TPOh/h primary recipients
and transplanted them in equally low numbers (100,000 CD34+
cells per animal) into Rag2−/−γc−/− newborn mice. Bone marrow
of secondary recipients was analyzed 8 wk later (Fig. 5H). Human
CD34+ cells isolated from TPOm/m primary recipients had a very
low capacity to serially engraft, because human CD45+ cells were
detected in only 2 of 11 secondary recipients. By contrast, human
CD45+ cells were present in the bone marrow of 15 of 19 mice
engrafted with CD34+ cells isolated from TPOh/h primary recip-
ients (P = 0.0012). Because the genotype of the secondary re-
cipient mice was the same for both groups (TPOm/m), this result
indicates that the presence of human TPO in the primary recip-
ient favored the maintenance of human cells with enhanced self-
renewal capacity.
Taken together, these results demonstrate that homozygous
TPO-humanized mice represent a better environment to main-
tain self-renewal capacity and multilineage differentiation po-
tential of human hematopoietic stem and/or progenitor cells.
Discussion
Signiﬁcant progress has been achieved in the development of
mice that sustain differentiation and function of the human
hematolymphopoietic system since the publication of the ﬁrst
models more than two decades ago (3, 4, 7, 8). However, several
limitations remain, including (i) human cell engraftment is only
transient, not lasting for the life of recipient mice (which could
be due to the inherent low frequency of long-term HSC in the
human CD34+ cell population, as well as to the suboptimal en-
vironment provided by the mouse host), (ii) the unphysiological
bias toward the lymphoid lineage as well as poor differentiation of
myeloid cells, and (iii) the variability in the engraftment levels
between different individual animals, even when groups of mice
are transplanted with cells from a single human donor. These
limitations might be due to nonphysiologic location of human
cells, residual xenoreactivity of the immunodeﬁcient host, dif-
ferent composition of hematolymphoid cells in mouse and human
species, and/or due to lack or insufﬁcient mouse-to-human cross-
reactivity of hematopoiesis supporting factors, leading to prefer-
ential mouse cell support (13, 15). Here, we describe a unique
strain of recipient mice in which we humanized the gene encoding
thrombopoietin, a cytokine with important functions in the
maintenance and self-renewal of HSCs.
Upon engraftment of these mice with human CD34+, we ob-
served signiﬁcant improvement in all three limitations listed
above: bone marrow chimerism was higher and was maintained
for at least 6 mo; multilineage, particularly myeloid lineage dif-
ferentiation was enhanced; and variability in engraftment levels
was reduced.
The concentrations of human TPO in the knock-in mice was
≈10-fold lower than the concentrations of mouse TPO, reﬂecting
the physiological values in each species. A priori, it could be
possible that the observed effect of the gene replacement is the
result of a knock down of TPO expression leading to decreased
mouse hematopoiesis and a concomitant competitive advantage
for human cells, rather than a speciﬁc positive effect of human
TPO.However, the analysis of heterozygous TPOh/m suggests that
this hypothesis is unlikely, although such a competitive advantage
probably contributes to the improved human cell engraftment.
Speciﬁcally, the heterozygous replacement of the Tpo gene in
TPOh/m mice leads to a defect in mouse HSCs that is not further
exacerbated by the elimination of the second copy of the mouse
gene in TPOh/h mice (Fig. 5 A and B). If the defect in mouse HSC
was the only factor responsible for enhanced human hematopoi-
esis, we should observe the same increase in human hematopoiesis
in TPOh/m as that observed in TPOh/h because both have the same
degree of reduction of mouse HSCs. However, we did not observe
any enhanced engraftment in TPOh/m compared with TPOm/m
recipients (Fig. S2E). Therefore, superior human hematopoiesis is
achieved in TPOh/h mice where (i) mouse HSCs are defective,
potentially increasing the space available for human cells and (ii)
two copies of the human TPO gene are present to support human
cell development. Both effects likely contribute to the increased
human engraftment; moreover, these results argue that both genes
are haploinsufﬁcient.
Fig. 4. Improved multilineage hematopoiesis in human TPO knock-in mice.
(A) Representative FACS analysis of human myeloid cell populations in bone
marrow. (Right) DiffQuick staining of hCD45+SSChiCD33+CD66hi cells puriﬁed
from the bone marrow of TPOh/h recipients. (B–D) Absolute numbers of
human myeloid cell populations in bone marrow (n = 19). (B) Total myeloid
populations (CD33+ cells). (C) Granulocytes (CD33+CD66hi). (D) Monocytes
(CD33+CD66loCD14+). (E) FACS analysis of the myeloid progenitors pop-
ulation, based on the expression of CD123 and CD45RA, among CD34+ cells
isolated from the bone marrow and gated on the Lin−CD38+ population. The
plots shown are representative of 3–5 mice per group.
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Besides its role in the regulation of the functional properties
of HSCs, TPO is a critical cytokine required for platelet de-
velopment. Replacement of the TPO-encoding gene leads to
a signiﬁcant decrease in mouse platelets. However, the human-
ization of TPO did not signiﬁcantly promote human thrombo-
poiesis. This result suggests that additional defects exist that
prevent adequate development of the human platelet forma-
tion. In fact, we detected only a very small fraction of the
Lin−CD34+CD38+CD45RA−CD123− (Fig. 4H), a population
phenotypically described as highly enriched in megakarycyte/
erythrocyte progenitors (MEPs) (30).
A major difference between the mouse and human immune
systems is the fraction of granulocytes present in the blood (36,
37). Lymphocytes are preponderant in mouse blood, whereas
human blood is rich in granulocytes, a difference unclear in its
signiﬁcance. Interestingly, the presence of human TPO im-
proved differentiation of human granulocytes (Fig. 4). Thus,
the presence of human TPO in recipient mice favors a balance
between granulocytes and lymphocytes that better reﬂects the
human physiological condition, a ﬁnding possibly due to better
maintenance and/or differentiation of human myeloid proge-
nitor cells.
More importantly, we show that TPO humanization favors the
maintenance of a human CD34+ population that can repopulate
human hematopoiesis in a secondary recipient (Fig. 5). Hence,
the Rag2−/−γc−/−TPOh/h mouse represents a unique model to
study various aspects of human stem and progenitor cell function
in vivo.
Despite the clear improvement in HSC-like cell populations,
as well as a better balance between the myeloid and lymphoid
lineages, we did not observe any signiﬁcant effect of TPO hu-
manization on the overall engraftment levels in peripheral lym-
phoid tissues or in the percentages of B and T cells (Fig. S5).
This result could be explained by different factors. (i) Although
the recipient mice are sublethally irradiated before trans-
plantation, a large population of radiation-resistant mouse my-
eloid cells is still present. Among those cells, macrophages are
able to phagocyte human cells and limit the overall engraftment
levels in the periphery (38–42). (ii) Human cells may require
additional factors to favor their terminal differentiation, egress
from the bone marrow, and/or their survival in the periphery.
(iii) Finally, although secondary lymphoid organs are formed in
humanized mice, their structure is not optimal compared with
human tissues (10, 13). This partially defective structure might
represent a limit to the number of human cells that can survive in
these organs. Thus, additional gene replacements will be neces-
sary to further improve the mouse recipients.
The two most widely used mouse models as recipients for
human hematopoietic cells are either the BALB/c Rag2−/−γc−/−
or the NOD-SCID γc−/− strains. Our approach required the
ability to serially target ES cells to efﬁciently introduce genetic
modiﬁcations into the mouse genome. Therefore, we chose to
use the heterozygote BALB/c × 129 genetic background, which
could be reproducibly and serially targeted by homologous re-
combination and retain viability and pluripotency. ES cells de-
rived from pure BALB/c and NOD genetic backgrounds have
become available recently, but serial targeting by homologous
recombination has yet to be shown.
With both BALB/c and NOD pure backgrounds, the inter-
pretation of the engraftment results are complicated by the high
variability between individual recipients. Although BALB/c and
129 alleles segregate randomly in our model, it does not seem to
drastically increase the variability compared with the results
reported with pure genetic backgrounds (10, 11, 43). Indeed,
despite this increased genetic variability, TPOh/h recipients pres-
ent more consistent levels of human chimerism in the bone
marrow than other models.
Several studies point to a superior capacity of NOD-SCID γc−/−
hosts to support human hematopoiesis compared with BALB/c
Rag2−/−γc−/−. A recent report (43), in which the authors per-
formed a comparison of different strains of recipient mice, shows
Fig. 5. Decreased mouse lin−c-Kit+Sca1+ cells and increased number and
self-renewal potential of human stem and progenitor cells in bone
marrow of human TPO knock-in mice. (A) Representative FACS analysis
of mouse Lin− Sca1+ c-Kit+ stem and progenitor cells in the bone marrow
of nonengrafted mice. Numbers indicate the percentage of Sca1+ c-Kit+
cells among the Lin− population. (B) Quantitative analysis of the results
presented in A. P = 0.0006 (one-way ANOVA; P values calculated with the
Tukey post hoc test; n = 5 per genotype; representative of two in-
dependent experiments). (C ) Representative FACS analysis of human
CD34+CD38− cells in the bone marrow. The numbers indicate the per-
centage of CD38− cells among the human CD45+CD34+ cells. (D) Quan-
titative analysis of the percentages of CD38− cells in the human
CD45+CD34+ population (n = 43–53). (E ) Absolute numbers of human
CD34+CD38− cells in the bone marrow of the same mice as in D. (F )
Representative FACS analysis of the hematopoietic stem and progenitor
cells, based on the expression of CD90 and CD45RA, among CD34+ cells
isolated from the bone marrow and gated on the Lin−CD38− population.
LT-HSC, long-term hematopoietic stem cells; MPP, multipotent progeni-
tors; MLP, multilymphoid progenitors. (G) Quantitative analysis of the
percentages of Lin−CD34+CD38−CD90+CD45RA− cells, as identiﬁed in F.
n = 6–8, from two experiments with 4- to 5-mo-old mice. (H) Human
CD45+CD34+ cells were puriﬁed from Rag2−/−γc−/− TPOm/m and TPOh/h
primary recipient mice, transplanted into newborn Rag2− /−γc− /− mice
(100,000 cells per mouse), and human CD45+ chimerism was determined
in secondary recipients 8 wk later. The results are pooled from two in-
dependent experiments (n = 7–12 primary recipients, n = 11–19 sec-
ondary recipients).









that it is particularly true for secondary lymphoid tissues. How-
ever, the human chimerism in the bone marrow and thymus is
comparable in NOD-SCID γc−/− and BALB/c Rag2−/−γc−/−.
Therefore, although we did not perform a direct side-by-side
comparison, these observations suggest that the TPOh/h mice re-
present an improvement relative to both BALB/c Rag2−/−γc−/−
and NOD-SCID γc−/− to study the bone marrow stages of human
hematopoiesis. Furthermore, the serial stepwise humanization of
additional genes, permitted by the use of BALB/c × 129 ES cells,
should further improve different aspects of human hematopoiesis
in our model in the near future.
In conclusion, with human TPO knockin mice, we provide
a unique model that can be useful to study in vivo physiology of
human hematopoiesis in general and human hematopoietic stem
and progenitor cells in particular. Moreover, we postulate that
these mice might be valuable to sustain in vivo human hemato-
poietic malignancies that originate from early hematopoietic
cells, such as myeloid leukemias and myeloproliferative neo-
plasias. More generally, we show that gene replacement is a pow-
erful strategy, which holds great promise to bring further prog-
ress to the ﬁeld of humanized mice.
Experimental Procedures
The human TPO knock-in mice were generated by using the VELOCI-
GENE (27) and VELOCIMOUSE (44) technologies, as described in the SI
Experimental Procedures.
Recipient mice were engrafted with human hematopoietic progenitors as
described (10). The mice were killed, and the engraftment of human he-
matopoietic cells was analyzed 3–4 or 6–7 mo later. All these procedures are
detailed in SI Experimental Procedures.
ACKNOWLEDGMENTS. We thank J. Alderman for organizational support;
A. M. Franco, P. Ranney, and R. Webber for human cell isolation and mouse
colony management; G. Lyon, L. Wan, S. Lin, and P. Ziegler for assistance with
materials and protocols; D. Krause for helpful discussion; Regeneron’s Veloc-
igene team for excellent technical contributions; and F. Manzo for manu-
script submission. This work was supported by grants from the Bill and
Melinda Gates Foundation through the Grand Challenges in Global Health
Initiative and from the Juvenile Diabetes Research Foundation. A.R. was sup-
ported by a D. Collen Fellowship of the Belgian American Educational Foun-
dation. R.A.F. is an Investigator of the Howard Hughes Medical Institute.
1. Kondo M, et al. (2003) Biology of hematopoietic stem cells and progenitors:
Implications for clinical application. Annu Rev Immunol 21:759–806.
2. Chao MP, Seita J, Weissman IL (2008) Establishment of a normal hematopoietic and
leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol 73:439–449.
3. McCune JM, et al. (1988) The SCID-hu mouse: Murine model for the analysis of human
hematolymphoid differentiation and function. Science 241:1632–1639.
4. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM (1988) Infection
of the SCID-hu mouse by HIV-1. Science 242:1684–1686.
5. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B (1992) Isolation of
a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89:
2804–2808.
6. Dick JE, Lapidot T (2005) Biology of normal and acute myeloid leukemia stem cells. Int
J Hematol 82:389–396.
7. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical
research. Nat Rev Immunol 7:118–130.
8. Legrand N, Weijer K, Spits H (2006) Experimental models to study development and
function of the human immune system in vivo. J Immunol 176:2053–2058.
9. Ito M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse
model for engraftment of human cells. Blood 100:3175–3182.
10. Traggiai E, et al. (2004) Development of a human adaptive immune system in cord
blood cell-transplanted mice. Science 304:104–107.
11. Ishikawa F, et al. (2005) Development of functional human blood and immune
systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood 106:1565–1573.
12. Gimeno R, et al. (2004) Monitoring the effect of gene silencing by RNA interference
in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: Functional
inactivation of p53 in developing T cells. Blood 104:3886–3893.
13. ManzMG (2007)Human-hemato-lymphoid-systemmice: Opportunities and challenges.
Immunity 26:537–541.
14. Allsopp RC, Cheshier S, Weissman IL (2001) Telomere shortening accompanies
increased cell cycle activity during serial transplantation of hematopoietic stem cells.
J Exp Med 193:917–924.
15. Legrand N, et al. (2009) Humanized mice for modeling human infectious disease:
Challenges, progress, and outlook. Cell Host Microbe 6:5–9.
16. Wendling F, et al. (1994) cMpl ligand is a humoral regulator of megakaryocytopoiesis.
Nature 369:571–574.
17. Kaushansky K, et al. (1994) Promotion of megakaryocyte progenitor expansion and
differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568–571.
18. Lok S, et al. (1994) Cloning and expression of murine thrombopoietin cDNA and
stimulation of platelet production in vivo. Nature 369:565–568.
19. de Sauvage FJ, et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis
by the c-Mpl ligand. Nature 369:533–538.
20. Bartley TD, et al. (1994) Identiﬁcation and cloning of a megakaryocyte growth and
development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117–1124.
21. Kaushansky K (1998) Thrombopoietin. N Engl J Med 339:746–754.
22. Kaushansky K (2008) Historical review: Megakaryopoiesis and thrombopoiesis. Blood
111:981–986.
23. Fox N, Priestley G, Papayannopoulou T, Kaushansky K (2002) Thrombopoietin
expands hematopoietic stem cells after transplantation. J Clin Invest 110:389–394.
24. Kirito K, Fox N, Kaushansky K (2003) Thrombopoietin stimulates Hoxb4 expression:
An explanation for the favorable effects of TPO on hematopoietic stem cells. Blood
102:3172–3178.
25. Yoshihara H, et al. (2007) Thrombopoietin/MPL signaling regulates hematopoietic
stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1:
685–697.
26. Qian H, et al. (2007) Critical role of thrombopoietin in maintaining adult quiescent
hematopoietic stem cells. Cell Stem Cell 1:671–684.
27. Valenzuela DM, et al. (2003) High-throughput engineering of the mouse genome
coupled with high-resolution expression analysis. Nat Biotechnol 21:652–659.
28. Ghilardi N, Wiestner A, Skoda RC (1998) Thrombopoietin production is inhibited by
a translational mechanism. Blood 92:4023–4030.
29. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC (1998) An activating splice
donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.
Nat Genet 18:49–52.
30. Manz MG, Miyamoto T, Akashi K, Weissman IL (2002) Prospective isolation of
human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 99:
11872–11877.
31. Hao QL, Thiemann FT, Petersen D, Smogorzewska EM, Crooks GM (1996) Extended
long-term culture reveals a highly quiescent and primitive human hematopoietic
progenitor population. Blood 88:3306–3313.
32. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Puriﬁcation of primitive human
hematopoietic cells capable of repopulating immune-deﬁcient mice. Proc Natl Acad
Sci USA 94:5320–5325.
33. Larochelle A, et al. (1996) Identiﬁcation of primitive human hematopoietic cells
capable of repopulating NOD/SCID mouse bone marrow: Implications for gene
therapy. Nat Med 2:1329–1337.
34. Majeti R, Park CY, Weissman IL (2007) Identiﬁcation of a hierarchy of multipotent
hematopoietic progenitors in human cord blood. Cell Stem Cell 1:635–645.
35. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC (1997) Assay of human stem cells by
repopulation of NOD/SCID mice. Stem Cells 15(Suppl 1):199–203; discussion 204–207.
36. Haley PJ (2003) Species differences in the structure and function of the immune
system. Toxicology 188:49–71.
37. Mestas J, Hughes CC (2004) Of mice and not men: Differences between mouse and
human immunology. J Immunol 172:2731–2738.
38. Rozemuller H, et al. (2004) Enhanced engraftment of human cells in RAG2/gammac double-
knockout mice after treatment with CL2MDP liposomes. Exp Hematol 32:1118–1125.
39. Takenaka K, et al. (2007) Polymorphism in Sirpa modulates engraftment of human
hematopoietic stem cells. Nat Immunol 8:1313–1323.
40. Takizawa H, Manz MG (2007) Macrophage tolerance: CD47-SIRP-alpha-mediated
signals matter. Nat Immunol 8:1287–1289.
41. Jaiswal S, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells
and leukemia cells to avoid phagocytosis. Cell 138:271–285.
42. Chao MP, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote
phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699–713.
43. Brehm MA, et al. (2010) Parameters for establishing humanized mouse models to
study human immunity: Analysis of human hematopoietic stem cell engraftment in
three immunodeﬁcient strains of mice bearing the IL2rgamma(null) mutation. Clin
Immunol 135:84–98.
44. Poueymirou WT, et al. (2007) F0 generation mice fully derived from gene-targeted
embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol 25:
91–99.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1019524108 Rongvaux et al.
